The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
First GMP batch released at Lonza’s next-generation mammalian manufacturing facility in Portsmouth (US)
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Lonza plans to invest approximately CHF 500 million to upgrade the facility
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The instrument is fully integrated with Lonza’s latest WinKQCLSoftware to enable data integrity compliance, streamline training, and reduce validation burden
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
